Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
LIPIODOL (Guerbet Australia Pty Ltd)
Product name
LIPIODOL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 working days (255)
Active ingredients
iodised oil
Registration type
EOI
Indication
In interventional radiology
LIPIODOL (solution for injection) is now also indicated as an imaging agent for visualisation and localisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma (HCC) at intermediate stage in adults (see section 4.3 -Contraindications and Section 4.4 Special Warnings and Precautions for Use).